In Spain last winter, something remarkable happened: paediatric wards fell silent. “Hospitals were empty, and nobody could believe it,” said Dr Javier Díez-Domingo, director of the Vaccine Research Centre in Valencia.  After the country introduced monoclonal antibodies against Respiratory Syncytial Virus (RSV) for every infant, RSV-related hospitalisations dropped by 83%. Thousands of healthy babies stayed … Continue reading Immunising for Prosperity: Why Europe Must Treat RSV and Pneumococcal Jabs an Economic Imperative